Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Drug Class (Bronchodilators (Beta 2-Agonists, Anticholinergics, Theophyllines), Phosphodiesterase Type 4 Inhibitors, Corticosteroids, Others), By Route of Administration (Oral and Inhalation), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East and Africa)

Published In : May 2024

Code : CMI2656

Pages :178

Formats :

Excel and PDF

Industry : Pharmaceutical

Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Trends

Global chronic obstructive pulmonary disease (COPD) treatment market is estimated to be valued at USD 19.21 Bn in 2024 and is expected to reach USD 28.37 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 5.7% from 2024 to 2031.

Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Key Factors

To learn more about this report, Request sample copy

Global chronic obstructive pulmonary disease (COPD) treatment market has been witnessing growth over the past few years due to huge adoption of inhaled medications and bronchodilators for management of COPD symptoms. Furthermore, pipeline drugs with novel mechanisms of action are being evaluated for treatment of COPD, and this can expand therapeutic options. Many pharmaceutical companies are also investing heavily in development of combination therapies to ensure better treatment outcomes. However, high treatment costs can hamper the market growth. Increasing global disease burden of COPD supported by growing awareness regarding its management can boost demand for COPD therapeutics during the forecast period.

Increasing Research and development Activities by Key Market Players

Increasing research and development activities by key market players is expected to drive the market growth over the forecast period. For instance, on March 14, 2024, AstraZeneca, a global pharmaceutical company, announced that its triple combination inhaled therapy- Breztri Aerosphere (budesonide/glycopyrrolate/formoterol fumarate) will be evaluated in a new phase 3 trial in patients with chronic obstructive pulmonary disease (COPD) and elevated cardiopulmonary risk.

Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Concentration By Players

To learn more about this report, Request sample copy

Increasing Awareness about Chronic Obstructive Pulmonary Disease (COPD)

Increasing adoption of inorganic growth strategies such as investments and fundings is expected to drive the market growth over the forecast period. For instance, in November 2021, according to the data published by the National Heart, Lung and Blood Institute, each November, the chronic obstructive pulmonary disease (COPD) community comes together to promote better understanding of chronic obstructive pulmonary disease (COPD), a progressive lung disease that affects millions across the US. Increasing awareness about chronic obstructive pulmonary disease (COPD) and its symptoms is important because early diagnosis and treatment can improve quality of life.